title: Selective CD27+ (memory) B cell reduction and characteristic B cell alteration in drug-naive and HAART-treated HIV type 1-infected patients.
abstract: To investigate HIV-1-related B cell disorders, the quantity of CD27 positive (CD27+) B cells and their CD38, CD95, and bcl-2 intensities were examined by flow cytometry analysis in 16 drug-naive patients, 27 highly active antiretroviral therapy (HAART)-treated patients, and 20 uninfected controls. CD27+ B cells have been recognized as memory B cells. The mean percentage of CD27+ B cells was significantly lower in drug-naive patients (11.9%) and in HAART-treated patients (16.1%) than in controls (31.4%) (p < 0.01). The intensities of CD38 and CD95 on CD27+ B cells were higher in drug-naive patients than in controls (p < 0.01 in CD95). The intensity of CD95 on CD27+ B cells in HAART-treated patients was lower than that of drug-naive patients, but significantly higher than that of controls (p < 0.01). The intensity of bcl-2 on CD27+ B cells was equivalent among the three groups. These findings suggest that disturbance of peripheral B cell composition, exemplified by CD27+ B cell reduction, exists in both drug-naive and HAART-treated HIV-1-infected patients. In addition, the augmented apoptotic state of CD27+ B cells found in HAART-treated patients with undetectable viral loads, indicated by CD95 elevation, suggests that some HIV-1-related B cell disorders last for years after effective antiviral therapy.
authors.affiliation: Department of General Medicine, Kyushu University, Fukuoka 812-8582, Japan.
authors.forename: Yong
authors.initials: Y
authors.lastname: Chong
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ikematsu
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Masayuki
authors.initials: M
authors.lastname: Murata
authors.forename: Mika
authors.initials: M
authors.lastname: Nishimura
authors.forename: Shigeki
authors.initials: S
authors.lastname: Nabeshima
authors.forename: Seizaburo
authors.initials: S
authors.lastname: Kashiwagi
authors.forename: Jun
authors.initials: J
authors.lastname: Hayashi
mesh_terms: D036541:ADP-ribosyl Cyclase / Q000378:metabolism; D051997:ADP-ribosyl Cyclase 1; D000328:Adult; D015703:Antigens, CD / Q000378:metabolism; D023241:Antiretroviral Therapy, Highly Active; D016175:B-Lymphocyte Subsets / Q000276:immunology*; D016022:Case-Control Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology*; D015497:HIV-1; D006801:Humans; D007156:Immunologic Memory; D008562:Membrane Glycoproteins; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000378:metabolism*; D019014:fas Receptor / Q000378:metabolism
chemical_list: D015703:Antigens, CD; D008562:Membrane Glycoproteins; D019253:Proto-Oncogene Proteins c-bcl-2; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D019014:fas Receptor; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1